Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238


Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up.

Mauri FA, Maisonneuve P, Caffo O, Veronese S, Aldovini D, Ferrero S, Cozzaglio F, Dalla Palma P, Galligioni E, Barbareschi M.

Int J Oncol. 1999 Dec;15(6):1137-47.


Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.

Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Boracchi P, Fanelli M, Tominaga T.

Int J Oncol. 1998 May;12(5):1117-25.


Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.


Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.


Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?

Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, Keramopoulos A, Michalas S.

J Surg Res. 2001 Aug;99(2):161-8.


The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.

Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U.

J Natl Cancer Inst. 1994 Apr 6;86(7):499-504.


Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up.

Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Palma PD, Harris AL, Barbareschi M.

Clin Cancer Res. 1996 Sep;2(9):1591-9.


A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.

Breast Cancer Res. 2008;10(5):R74. doi: 10.1186/bcr2139. Epub 2008 Sep 4.


Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up.

Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla Palma P, Harris A.

Hum Pathol. 1996 Nov;27(11):1149-55.


Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.

Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S.

J Am Coll Surg. 2004 Jan;198(1):83-90.


Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group.

J Clin Oncol. 2008 Mar 20;26(9):1419-26. doi: 10.1200/JCO.2007.14.5565. Epub 2008 Feb 19.


The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.

Alexieva-Figusch J, Van Putten WL, Blankenstein MA, Blonk-Van Der Wijst J, Klijn JG.

Cancer. 1988 Feb 15;61(4):758-68.


Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.

J Clin Oncol. 2007 Sep 1;25(25):3846-52. Epub 2007 Aug 6.


Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.

Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B; International Breast Cancer Study Group.

J Natl Cancer Inst. 2006 Nov 1;98(21):1571-81.


Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma.

Sebastiani V, Botti C, Di Tondo U, Visca P, Pizzuti L, Santeusanio G, Alo PL.

Anticancer Res. 2006 Jul-Aug;26(4B):2983-7.


Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.

el-Ahmady O, el-Salahy E, Mahmoud M, Wahab MA, Eissa S, Khalifa A.

Anticancer Res. 2002 Jul-Aug;22(4):2493-9.


Supplemental Content

Support Center